ANG Lifesciences India Ltd. engages in the manufacture and marketing of finished pharmaceutical formulations in a form of sterile dry powder for injection vials. The company is headquartered in Amritsar, Punjab. The company went IPO on 2017-09-08. The firm is engaged in the business of manufacturing and marketing of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials. The Company’s product portfolio includes antibiotics, antiulcerant, neutraceuticals, anticoagulants, glucocorticoids, anti-inflammatory, antifungal, antihistamines, antimalarial, and anesthetic. Its dosage forms manufactured by Company includes tablets, capsules, oral liquids, liquid injection, prefilled syringe (PFS), dry powder injection and external preparations. The Company’s manufacturing unit is situated at Village Kishan pura, Post office Manpura Baddi Nalagarh Road, Tehsil Nalagarh, District Solan, Himachal Pradesh. The firm manufactures its products in compliance with good manufacturing practices (GMP) requirements.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.